Some Vaccines Help Nations Exit the Pandemic Faster Than Others
(Bloomberg) -- With hundreds of millions of people now vaccinated against Covid-19, the coronavirus outbreak should begin to die down in places where a large chunk of the population has been inoculated. But that isn’t happening everywhere.
Instead, two paths are emerging: In countries such as Israel, new Covid cases are declining as vaccinations spread, while in other places like the Seychelles -- which has fully inoculated more of its population than any other nation -- infections continue to increase or even reach new highs.
One reason for that may be the different types of vaccine being used. Evidence derived from the expanding global inoculation rollout indicates that the messenger RNA shots developed by Moderna Inc. or Pfizer Inc. and BioNTech SE are better at stopping people from becoming contagious, helping reduce onward transmission -- an unexpected extra benefit as the first wave of Covid vaccines were intended to stop people from becoming very sick.
Other vaccines, while effective in preventing acute illness or death from Covid, appear not to have this extra perk to the same degree.
“This will be an increasing trend as countries start to realize that some vaccines are better than others,” said Nikolai Petrovsky, a professor at the College of Medicine and Public Health at Flinders University in South Australia. While the use of any vaccine “is still better than nothing,” he said, some doses “may have little benefit in preventing spread, even if they reduce the risk of death or severe disease.”
Studies of millions of people in Israel vaccinated with the Pfizer-BioNTech shot show the mRNA doses prevented more than 90% of asymptomatic infections -- those who contract the virus but show no symptoms. That’s important, said Raina MacIntyre, an epidemiologist at the University of New South Wales in Sydney, because a vaccine’s ability to stop asymptomatic infection “is the determinant of whether or not herd immunity is possible.”
Herd immunity is typically achieved when the virus can no longer find any vulnerable hosts in order to keep spreading.
Which vaccines a country can secure could therefore affect everything from policy about mask-wearing and social distancing to lifting border restrictions and reviving economies, given the influence that daily case counts have on government decisions. For individuals it may determine how soon they regain pre-pandemic freedoms.
The differences in effectiveness are already leading to preferred brands in countries where more than one vaccine is available. In the Philippines, immunization centers have been instructed not to announce which shots are being given after a crowd turned up at one location hoping to get access to the Pfizer shot.
In the U.S., nearly 40% of the population has been fully vaccinated, mostly with mRNA shots, and the number of new cases each day has dropped by more than 85% in the past four months. The Centers for Disease Control and Prevention this month said those who are fully vaccinated can gather without masks or social distancing.
“If you are fully vaccinated, you can start doing things you have stopped doing because of the pandemic,” said CDC director Rochelle Walensky, “we have all longed for this moment, when we can get back to some sense of normalcy.”
A similar trajectory is evident in Israel, which fully vaccinated nearly 60% of its population with the Pfizer-BioNTech shot and has gradually lifted restrictions as new cases declined to fewer than 50 a day, from more than 8,000 at the beginning of this year. Qatar and Malta are also witnessing a decline in new cases after giving around 30% of their populations two doses of mostly mRNA vaccines.
The results provide further evidence of the surprise efficacy of the new mRNA shots; the pandemic is the first time this vaccine technology is being widely used. They work by delivering genetic codes that instruct the human body to make proteins of the virus that in turn stimulate an immune response.
The existing mRNA shots require ultra cold storage, limiting their accessibility to countries with poor transport and storage infrastructure.
That’s one reason why most countries, though, are relying predominantly on non-mRNA shots ranging from the adenovirus vector vaccines from AstraZeneca Plc, to those from Chinese developers Sinopharm and Sinovac Biotech Ltd. that use an inactivated form of the virus. These more traditional vaccine types have shown efficacy rates of between 50% to 80% in preventing symptomatic Covid in clinical trials, compared with more than 90% for mRNA ones. There’s little data regarding their ability to prevent onward transmission, but signs are emerging that it may be much lower.
“Real-world evidence is difficult to compare as it is captured at different times, in different populations, in different places that may have different levels of Covid-19 infection and with different variants of the virus in circulation,” a spokesperson for AstraZeneca said following publication of this story. “Comparing vaccines data is complex and must take many factors into account.”
The company pointed to newly released real-world data from the U.K. as evidence of the shot’s benefits: two doses of the AstraZeneca vaccine is around 85% to 90% effective against symptomatic disease, said Public Health England on Thursday.
This is higher than the 66.7% efficacy rate found in clinical trials, though data is not yet available on the vaccine’s ability to prevent asymptomatic infection in the real world.
Sinopharm didn’t immediately respond to queries for this story.
An archipelago in the Indian Ocean, the Seychelles has fully vaccinated about 65% of its population with AstraZeneca and Sinopharm shots, yet weekly new infections increased rapidly this month, with 37% of those patients having already received their two doses. The surge led authorities to close schools, cancel sporting events and ban household gatherings. Among fully inoculation people, around 60% received the vaccine from Sinopharm and the rest got AstraZeneca’s shot.
In Chile in South America, the steady ramp-up in vaccination using mostly Sinovac’s shot didn’t prevent the number of new daily cases from almost doubling in mid-April from a month earlier, despite administering enough doses to cover 30% of the population. Authorities had to reintroduce a lockdown across the country in late March.
But in the case of both countries, the type of vaccine available seems to be only one of many factors affecting the spread of the disease. Policy failures in places that reacted too slowly to impose restrictions, or lifted them prematurely, have been a major contributor, as has speed of diagnosis and access to medical facilities. Different transmission rates of virus variants also play a part.
Seychelles President Wavel Ramkalawan said transmission increased in his country after the nation’s world-beating vaccine roll-out caused people to let down their guard.
The uptick in infections in Chile was attributed by Sinovac’s Chief Executive Officer Yin Weidong to the nation prioritizing elderly people in their initial vaccination efforts. “It’s normal that the country sees a resurgence of infections as social activities increase among the younger people who are mainly not inoculated,” he said in a May 11 interview.
|AstraZeneca (Adenovirus vector)||66.7%||22.2%||54.1%|
* Note: Data for Pfizer and Sinovac vaccine is from real world studies in Israel and Chile respectively, while that for AstraZeneca is from its clinical trials.
What seems clear is that all the approved doses reduce the incidence of people becoming severely ill or dying from the disease -- the primary goal of a vaccine. That takes pressure off hospitals and medical resources. Most new Covid patients in the Seychelles, for example, are only experiencing mild symptoms, according to the nation’s president.
This is a crucial first step for countries without access to mRNA vaccines, said Helen Petousis-Harris, a vaccinologist at the University of Auckland. After using available vaccines to crush the number of severe cases, countries can stamp out remaining infection with shots that curb transmission once they become available.
Another possibility is that vaccination along with the spread of mild cases could also end up building so-called herd immunity, said Ben Cowling, head of the University of Hong Kong’s department of epidemiology and biostatistics. “The places with less immunity against infection but more immunity against severe disease will see circulation of the virus causing mainly mild infections, boosting immunity to a higher level.”
Experts say a lot remains unknown and so-called breakthrough infections -- where people who received shots still get Covid -- do occur, even with mRNA vaccines. It’s also not yet fully known how well the different kinds of shots perform against the different variants of the virus.
A study conducted in Qatar among some 260,000 people who completed two doses of Pfizer-BioNTech’s vaccine showed the mRNA shot’s effectiveness at preventing infections caused by the South African variant dipping to 75%.
The improvements in the U.S and Israel came before those places were affected by concerning new strains, which include variants that have emerged in Brazil and India.
“I would be careful about over-interpreting the data,” said Petrovsky at Flinders University, who points out that no head-to-head studies -- where shots are tested against each other -- have been performed to identify the best vaccines. For the mRNA shots, “data on their effects on transmission is very limited.”
In the end, it may need the development of new, modified versions of the vaccines to finally win the war against Covid, said Petousis-Harris. Some vaccine developers are working on nasal spray inoculations, which can prevent the virus from taking hold in the respiratory track, thus cutting off infection at its entry point.
“We’ve got some super vaccines that are beyond expectation,” she said. “We’ve learned a lot and so imagine what the next one is going to look like.”
©2021 Bloomberg L.P.